protein design, Quartals-Zahlen ??? - 500 Beiträge pro Seite

[hk2000]

hallo zusammen,
kennt jemand schon einen ausblick auf die Q-Zahlen von pdli ? Sollen heute veröffentlicht werden.

gruß hk2000

[FauleSau]

Man rechnet mit 0,07 pro Aktie!


Ciao!

[TheRed]

http://earnings.nasdaq.com/earnings/earnings_forecast.asp?sy…

7,3 Cents pro Aktie (hoch 11 Cents, niedrig 5 Cents)
6 Analysten.

Heute nach Börsenschluß

[hk2000]

vielen dank für die infos !

Heute schwächelt der kurs von PDLI, wird sich das nach der veröffentlichung der zahlen ändern ?

gruß hk2000

[AldoBaran]

Hier die Meldung/Zahlen:
(erwartungen werden weit übertroffen, aber der Ausblick scheint
mir nicht sehr gut)

PROTEIN DESIGN LABS ANNOUNCES FIRST QUARTER 2001
FINANCIAL RESULTS

Fremont, CA, May 14, 2001 - Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI)
today reported net income of $6.6 million, or $0.15 per basic and $0.14 per
diluted share, for the three months ended March 31, 2001, compared with net
income of $0.8 million, or $0.02 per basic and diluted share, for the three
months ended March 31, 2000.

Revenues during the 2001 first quarter totaled $26.2 million, a 69% increase
over the $15.5 million in revenues reported for the 2000 first quarter.
Revenues in the 2001 first quarter included royalties, a signing and
licensing fee, milestone payments, portions of upfront fees paid to PDL
pursuant to humanization agreements, a license maintenance fee and interest
income. Revenues under agreements with third parties were $16.7 million in
the quarter ended March 31, 2001, compared with $12.5 million for the
corresponding 2000 quarter.

Total costs and expenses in the 2001 first quarter were $19.5 million,
compared with $14.7 million in the first quarter of 2000. Research and
development expenses were $13.7 million in the first quarter of 2001,
compared with $11.1 million in the year-earlier period. General and
administrative expenses were $3.6 million and $2.5 million in the 2001 and
2000 first quarters, respectively. Interest expense was $2.2 million in the
2001 first quarter compared with $1.2 million in the first quarter of 2000.

At March 31, 2001, PDL had cash, cash equivalents and investments totaling
$665.7 million, compared with $661.2 million at December 31, 2000.

Outlook

The following paragraph provides forward-looking financial guidance that PDL
believes to be correct as of May 14, 2001. This guidance is unchanged from
that provided in PDL`s last financial press release issued on February 13,
2001. PDL does not plan to update this information until its next financial
press release and expressly disclaims any duty to update information
contained in this press release.

For the year ending December 31, 2001, PDL currently anticipates total costs
and expenses will increase approximately 20-25% compared with total costs
and expenses in 2000. Revenues are expected to include royalty revenues,
portions of upfront fees paid to PDL pursuant to humanization agreements,
milestone payments, maintenance payments for patent licenses, patent license
fees and interest income. The timing and amounts of non-interest revenues
are dependent upon numerous factors and may be particularly dependent upon
the seasonality of sales of licensed products, including Synagis* from
MedImmune, Inc., and our ability to enter into new collaborative,
humanization, and patent licensing agreements, as well as our ability to
recognize revenue under any new and existing agreements. As a result, PDL
is not providing guidance with respect to its expected quarterly financial
results for 2001. For the fiscal year ending December 31, 2001, PDL
currently expects to approximately break even.

PDL will webcast a conference call live at 4:30 p.m. Eastern time today to
review its 2001 first quarter financial results. A link to the conference
call webcast will be available through the PDL website: www.pdl.com.
Please connect to this website at least 15 minutes prior to the conference
call to ensure adequate time for any software download that may be needed to
hear the webcast. A replay of the webcast will be available from
approximately one hour after the call through 11:59 p.m. Eastern time on May
21, 2001. A replay of the conference call will also be available by
telephone from approximately 6:30 p.m. Eastern time today through May 21,
2001. To access the replay, dial 800-642-1687 from inside the U.S. and
706-645-9291 from outside the U.S. and enter conference ID number 838484.

The foregoing contains forward-looking statements involving risks and
uncertainties and PDL`s actual results may differ materially from those,
express or implied, in the forward-looking statements. Factors that may
cause such differences include, but are not limited to, the following:
Financial results for the fiscal year ending December 31, 2001 are dependent
on the level of revenues and expenses recognized by PDL, both of which are
unpredictable and may fluctuate from quarter to quarter. Our expenses
depend in part on the timing of expenses, which may include payments by us
and to us under collaborative agreements for reimbursement of expenses and
which are reported under our policy during the quarter such expenses are
reported to us or to our collaborative partners and agreed to by us or our
partner. Our revenues depend on numerous factors and may be particularly
dependent upon the seasonality of sales of licensed products, including
Synagis* from MedImmune, Inc., and our ability to enter into new, if any,
collaborative, humanization, and patent licensing agreements and our ability
to recognize revenue under any new and existing agreements. In addition,
other factors which may cause our actual results to differ materially from
those, express or implied, in the forward-looking statements in this press
release are discussed in our Annual Report on Form 10-K for the year ended
December 31, 2000 and other filings made with the Securities and Exchange
Commission.

Protein Design Labs is a leader in the development of humanized antibodies
to prevent or treat various disease conditions. PDL currently has antibodies
under development for autoimmune and inflammatory conditions, asthma and
cancer. PDL holds fundamental patents in the U.S., Europe and Japan for its
antibody humanization technology. Further information on PDL is available
at www.pdl.com.

Protein Design Labs and the PDL logo are registered U.S. trademarks of
Protein Design Labs, Inc. Synagis is a registered U.S. trademark of
MedImmune, Inc.

Financial table is attached.
<<Q101PRv11.xls>>

[hk2000]

Protein Design Labs, Inc. (PDLI) led the earnings parade tonight, rising 0.30 to
55.80 on Island. The Fremont, CA developer of human and humanized antibodies
announced earnings after the bell today of $0.14 per diluted share, doubling
analysts estimates of .07 per share.

> Verdoppelung der Analysten-Erwartungen und als Aussicht
auf das gesamte Jahr 2001 den break-even zu halten.
Nach meiner Meinung klingt das doch ganz akzeptabel.

[hk2000]

Das US-Unternehmen Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI) hat auf dem zweiten Treffen des »Internationalen Psoriasis Symposiums« und dem »Europäischen Kongress für Psoraisis« in San Francisco über seine drei experimentellen humanisierten Antikörper, zur Therapie von Psoriasis (Schuppenflechte), berichtet. Auf dem Symposium, welches unter dem Titel »Die immunologische Basis zur Behandlung von Psoriasis: Neue zellgerichtete Therapien« läuft, hat u. a. Daniel Levitt, M.D., Ph.D., von Protein Design Labs über die drei aussichtsreichen Produktkandidaten referiert. PDL verfolgt bei seinen Therapieansätzen zur Behandlung der Schuppenflechte mehrere Möglichkeiten, sagte Dr. Levitt. Dazu führt PDL derzeit klinische Studien mit Antikörpern durch, die auf verschiedene Aspekte der T-Zellenfunktion, welche die grundlegende immunologische Basis bei der Entstehung von Psoriasis darstellen, zielen.

Der am weitesten in der Entwicklung fortgeschrittene Antikörper von PDL nennt sich Daclizumab (Zenapax), ist gegen die Alpha-Kette des humanen Interleukin-2 Rezeptors (CD25) gerichtet, dient der Aufrechterhaltung eines bestimmten Heilungszustandes und soll einen Rückfall möglichst verhindern. Die ersten Ergebnisse aus einer noch laufenden Phase II Studie sind laut Dr. Levitt mehr als ermutigend. Der zweite Antikörper in der Entwicklung trägt den Namen Nuvion und ist gegen CD3, ein Protein das Teil des T-Zellantigen-Rezeptor-Komplexes ist, gerichtet. Es wurden die positiven Ergebnisse einer Phase I/II Studie mit Nuvion diskutiert. Der dritte Antikörper im Bunde, SMART, ist gegen gamma-Interferon gerichtet, hat erfolgreich eine Phase I Studie beendet und soll laut PDL demnächst in einer weiteren Phase I/II Studie seine Sicherheit und Wirksamkeit bestätigen, daneben sollen, so Dr. Levitt, aber auch pharmakokinetische Aspekte geklärt werden.